Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-nivolumab and 18F-anti-PD-L1 PET as predictive imaging biomarkers in nivolumab-treated NSCLC
2015-004760-11Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Started Jun 2016; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-004760-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004760-11.